Progressive preclinical interstitial lung disease in rheumatoid arthritis.

BACKGROUND Early detection and treatment for interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) may ameliorate disease progression. The objective of this study was to identify asymptomatic lung disease and potential therapeutic targets in patients having RA and preclinical ILD (RA-ILD). METHODS Sixty-four adults with RA and 10 adults with RA and pulmonary fibrosis (RAPF) were referred to the National Institutes of Health, Bethesda, Maryland, and underwent high-resolution computed tomography (HRCT) and pulmonary physiology testing. Proteins capable of modulating fibrosis were quantified in alveolar fluid. RESULTS Twenty-one of 64 patients (33%) having RA without dyspnea or cough had preclinical ILD identified by HRCT. Compared with patients without lung disease, patients with RA-ILD had statistically significantly longer histories of cigarette smoking (P< .001), increased frequencies of crackles (P= .02), higher alveolar-arterial oxygen gradients (P= .004), and higher HRCT scores (P< .001). The HRCT abnormalities progressed in 12 of 21 patients (57%) with RA-ILD. The alveolar concentrations of platelet-derived growth factor-AB and platelet-derived growth factor-BB were statistically significantly higher in patients having RA-ILD (mean [SE], 497.3 [78.6] and 1473 [264] pg/mL, respectively) than in patients having RA without ILD (mean [SE], 24.9 [42.4] and 792.7 [195.0] pg/mL, respectively) (P< .001 and P=.047, respectively). The concentrations of interferon gamma and transforming growth factor beta(2) were statistically significantly lower in patients having RAPF (mean [SE], 5.59 [1.11] pg/mL and 0.94 [0.46] ng/mL, respectively) than in patients having RA without ILD (mean [SE], 14.1 [1.9] pg/mL and 2.30 [0.39] ng/mL, respectively) (P=.001 and P=.006, respectively) or with preclinical ILD (mean [SD], 11.4 [2.6] pg/mL and 3.63 [0.66] ng/mL, respectively) (P=.04 and P=.007, respectively). Compared with patients having stable RA-ILD, patients having progressive RA-ILD had statistically significantly higher frequencies of treatment using methotrexate and higher alveolar concentrations of interferon gamma and transforming growth factor beta(1) (P=.046, P=.04, and P=.04, respectively). CONCLUSIONS Asymptomatic preclinical ILD, which is detectable by HRCT, may be prevalent and progressive among patients having RA. Cigarette smoking seems to be associated with preclinical ILD in patients having RA, and treatment using methotrexate may be a risk factor for progression of preclinical ILD. Quantification of alveolar proteins indicates that potential pathogenic mechanisms seem to differ in patients having RA-ILD and symptomatic RAPF.

[1]  J. White,et al.  Pathogenesis of pulmonary fibrosis: platelet-derived growth factor precedes structural alterations in the Hermansky-Pudlak syndrome. , 1994, The Journal of laboratory and clinical medicine.

[2]  G J Roth,et al.  Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis , 2007, European Respiratory Journal.

[3]  J. Dawson,et al.  Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis , 2002, Annals of the rheumatic diseases.

[4]  J. Dawson,et al.  Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests , 2001, Thorax.

[5]  Y. Kaneda,et al.  In Vivo Gene Transfer of an Extracellular Domain of Platelet-Derived Growth Factor β Receptor by the HVJ-Liposome Method Ameliorates Bleomycin-Induced Pulmonary Fibrosis , 1999 .

[6]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[7]  T. Massey,et al.  Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[8]  J. Troendle,et al.  Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. , 2002, Molecular genetics and metabolism.

[9]  吉田 光宏.  A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor β1, or platelet-derived growth factor B Gene , 1997 .

[10]  W. Gahl,et al.  Pulmonary function and high-resolution CT findings in patients with an inherited form of pulmonary fibrosis, Hermansky-Pudlak syndrome, due to mutations in HPS-1. , 2000, Chest.

[11]  A. Brody,et al.  Differential proliferation of rat lung fibroblasts induced by the platelet-derived growth factor-AA, -AB, and -BB isoforms secreted by rat alveolar macrophages. , 1991, American journal of respiratory cell and molecular biology.

[12]  J. Lasky,et al.  Emphysematous lesions, inflammation, and fibrosis in the lungs of transgenic mice overexpressing platelet-derived growth factor. , 1999, The American journal of pathology.

[13]  E. Kazerooni,et al.  Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. , 2005, Arthritis and rheumatism.

[14]  A. Dwyer,et al.  Hermansky-Pudlak syndrome: radiography and CT of the chest compared with pulmonary function tests and genetic studies. , 2002, AJR. American journal of roentgenology.

[15]  Gary R. Grotendorst,et al.  Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. , 1987, The New England journal of medicine.

[16]  J. G. Weg,et al.  Pulmonary dysfunction in rheumatoid disease. , 1973, Chest.

[17]  H. Toutenburg,et al.  Lehmann, E. L., Nonparametrics: Statistical Methods Based on Ranks, San Francisco. Holden‐Day, Inc., 1975. 480 S., $ 22.95 . , 1977 .

[18]  A. Ullrich,et al.  Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors , 1986, Nature.

[19]  D. Morgan,et al.  Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. , 1999, The American journal of pathology.

[20]  R. Crystal,et al.  Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. , 1986, Journal of applied physiology.

[21]  M. Selman,et al.  Platelet-derived growth factor in idiopathic pulmonary fibrosis. , 1990, The Journal of clinical investigation.

[22]  A. Miller,et al.  Lung function testing: selection of reference values and interpretative strategies. , 1992, The American review of respiratory disease.

[23]  Y. Kaneda,et al.  A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Phillips,et al.  Two different subunits associate to create isoform-specific platelet-derived growth factor receptors. , 1989, The Journal of biological chemistry.